Ostial Corporation Appoints Mike Buck as Chief Executive Officer

Seasoned Medtech Executive Leads Company into Next Phase of Growth

CAMPBELL, CA – July 1, 2024 Ostial Corporation (Ostial), a private medical technology company focused on addressing the clinical challenges of aorto-ostial interventions, is pleased to announce the appointment of Mike Buck as its new Chief Executive Officer. Mike brings over 30 years of cardiovascular experience, having held several executive leadership positions at prominent companies, including Guidant, Abbott, Cardinal Health, and most recently, TRUVIC Medical.

"We are thrilled to welcome Mike to Ostial at such a pivotal point in our company’s growth trajectory," said Fred Khosravi, Chairman of the Board. "Given Mike’s proven track record of consistently delivering outstanding results throughout his career, combined with his deep industry knowledge, extensive operational experience, and commercial leadership, we have the utmost confidence in his ability to lead and transform Ostial through the next phase of the company."

Mike joins Ostial after serving as TRUVIC’s Founder and Chief Executive Officer. TRUVIC, now Imperative Care Vascular after its acquisition in 2021, was led by Mike from concept through commercialization of the company’s next generation thrombectomy solutions.

"I am honored and excited to join Ostial as CEO," said Mike Buck. "Delivering solutions that enable physicians to confidently treat vascular disease, while ensuring successful outcomes is our top priority. The FLASH System fulfills this commitment while serving as a platform for growth as we explore opportunities to bring additional innovative solutions to the market.”


About Ostial Corporation

Ostial Corporation, an Incept LLC portfolio company headquartered in Campbell, California, is a private medical technology company focused on addressing the clinical challenges of aorto-ostial interventions. The company's first product, the FLASH™ Aorto-Ostial Angioplasty System, allows physicians to confidently treat ostial cases with true, 360° lesion coverage that enables streamlined vessel reaccess and optimal patient outcomes. The company is supported by prominent investors, AMED Ventures and Delos Capital. For more information, visit www.ostialcorp.com.